Participants: healthy adults between the ages of 50 and 81
Dosage: 5 mg/week or 10 mg/week of rapamycin

One of the most potent anti-aging compounds rapamycin — an FDA-approved drug that inhibits mTOR — increases the lean body mass of older women while reducing their pain. 


Senior investigator Sajad Zalzala, MD (image: cnbc.com)

Clinical Trials

Cognitive deficits were reduced by 52% in Alzheimer’s disease patients receiving transcranial magnetic stimulation (TMS) — a technique that stimulates the brain’s electrical activity. 


Lead researcher Giocomo Koch, MD, PhD, uses a TMS device on an individual wearing an electroencephalogram (EEG) cap (image: domussantarita.it). 

Brain &amp; Neurons

The most comprehensive brain model reveals that combining NAD+ (nicotinamide adenine dinucleotide) supplementation with diet and exercise powerfully modulates brain aging. 


Model: Male C57BL/6 mice 
Dosage: 10 mg/kg of glyburide via intragastric injections or 500 mg/kg of NMN by oral water supply daily starting at 12 months of age until death

Common Diabetes Medication Extends Life, Suggests New Study

Researchers show that glyburide, an anti-diabetes drug, extends lifespan and reduces frailty in naturally aged mice.

(The chemical structure of glyburide, a diabetes medication | PubChem)

Aging &amp; Longevity

Esteemed Cardiologist Says Commercial Interests Are Distorting Evidence Behind Statins

Dr. Aseem Malhotra, a cardiologist from the UK, says pharmaceutical company-sponsored research distorts the scientific evidence behind the effectiveness of cholesterol-lowering statins against heart disease.

(Dr. Aseem Malhotra, cardiologist | The Telegraph)

Search Result: drugs

Anti-Aging Supplement Rapamycin Increases Muscle and Reduces Pain: New Results

Jumpstarting the Brain Reduces Alzheimer’s Progression by 52% in New Phase II Trial.

Most Comprehensive Study Places NAD+ at Forefront of Countering Brain Aging

Common Diabetes Medication Might Extend Life, Suggests New Study

Activist Cardiologist Says Commercial Interests Are Distorting Evidence Behind Statins